Noroozi’s findings indicated the efficacy of utilizing AAV vector for CRISPR/Cas9 delivery in targeting the HPV-E6 gene within HeLa cells, thereby enhancing tumor cell apoptosis and elevating p53 expression levels (Noroozi et al., 2022). Here, TP53 is linked to neoplasm.